NDLI: Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine

Content Provider	PubMed Central
Author	Bhutia, Yangzom D. Babu, Ellappan Ganapathy, Vadivel
Copyright Year	2016
Abstract	Tumour cell metabolism is very different from normal cell metabolism; cancer cells re-programme the metabolic pathways that occur in normal cells in such a manner that it optimizes their proliferation, growth and survival. Although this metabolic re-programming obviously operates to the advantage of the tumour, it also offers unique opportunities for effective cancer therapy. Molecules that target the tumour cell-specific metabolic pathways have potential as novel anti-cancer drugs. Lonidamine belongs to this group of molecules and is already in use in some countries for cancer treatment. It has been known for a long time that lonidamine interferes with energy production in tumour cells by inhibiting hexokinase II (HKII), a glycolytic enzyme. However, subsequent studies have uncovered additional pharmacological targets for the drug, which include the electron transport chain and the mitochondrial permeability transition pore, thus expanding the pharmacological effects of the drug on tumour cell metabolism. A study by Nancolas et al. in a recent issue of the Biochemical Journal identifies two additional new targets for lonidamine: the pyruvate transporter in the mitochondria and the H+-coupled monocarboxylate transporters in the plasma membrane (PM). It is thus becoming increasingly apparent that the anti-cancer effects of lonidamine do not occur through a single target; the drug works at multiple sites. Irrespective of the molecular targets, what lonidamine does in the end is to undo what the tumour cells have done in terms of re-programming cellular metabolism and mitochondrial function.
Related Links	http://dx.doi.org/10.1042/bcj20160068
Ending Page	1506
Page Count	4
Starting Page	1503
File Format	PDF
ISSN	02646021
e-ISSN	14708728
Journal	Biochemical Journal
Issue Number	11
Volume Number	473
Language	English
Publisher	Portland Press Ltd.
Publisher Date	2016-06-01
Access Restriction	Open
Rights Holder	Portland Press Ltd.
Subject Keyword	Cell Biology Biochemistry Molecular Biology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cell Biology Molecular Biology Biochemistry

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters

Re-examining HSPC1 inhibitors

Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.

AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases

3D tumour models: novel in vitro approaches to cancer studies

Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer

Mitochondrial metabolism in cancer stem cells: a therapeutic target for colon cancer

Stress eating and tuning out: Cancer cells re-wire metabolism to counter stress

Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine*

Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine

Similar Documents

The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters

Re-examining HSPC1 inhibitors

Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.

AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases

3D tumour models: novel in vitro approaches to cancer studies

Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer

Mitochondrial metabolism in cancer stem cells: a therapeutic target for colon cancer

Stress eating and tuning out: Cancer cells re-wire metabolism to counter stress

Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine*

Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine